Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Conditions
Metastatic Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
breast cancer, HER2, Trastuzumab, Lapatinib, HER2 gene-amplification
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Trastuzumab or Lapatinib
Type: Drug
Overall Status
Recruiting
Summary
This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion biological study will assess factors correlated with sensitivity or resistance to either one of the compounds
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Women aged 18-75 years

- Histologically or cytologically confirmed metastatic disease.

- HER2-Overexpression proven by Fluorescence in Situ Hybridization (FISH).

- Availability of paraffin-embedded block of either primitive tumor and/or biopsy of metastases.

- No prior chemotherapy for metastatic or locally advanced disease. Patients with hormone receptor (oestrogen and/or progesterone) positive breast cancer can be eligible provided that they had received only ONE line of hormonal therapy for metastatic disease.

- For patients undergoing hormonal therapy for metastatic disease, disease progression must be confirmed according to RECIST criteria.

- At least 20% increase in the sum of longest diameters, OR

- Evidence of new metastatic lesions or progression of pre-existing non-target lesions.

- Presence of at least one monodimensionally measurable lesion. Patients without clinically or radiologically proven evidence of disease are not eligible.

- Patients with exclusively skin disease are eligible, provided that the disease evolution under treatment can be photographically documented.

- Patients with involvement of NCS, besides presence of measurable lesions, are eligible provided that:

- Brain lesion/s has/have been radically resected;

- Brain lesion/s has/have obtained complete remission following radiation therapy. Complete remission must be documented by TC or RMN.

- At least 4-week interval from end of radiotherapy, hormono- or immunotherapy and enrollment in this study.

- ECOG PS
- Liver metastases involving < 30% of liver volume.

- Adequate hematopoietic, liver and renal function

- Written informed consent.

- Patients with childbearing potential must have negative pregnancy test and must use adequate contraceptive measures during treatment.

- Prior treatment with Trastuzumab as adjuvant therapy is permitted provided that it was completed at least 12 months prior enrollment in this study.

Exclusion Criteria:

- Prior chemotherapy for metastatic disease.

- Active pregnancy or breastfeeding.

- Previous treatment with Lapatinib.

- Previous therapy with mono- or policlonal antibodies for metastatic disease.

- Patients with bone involvement or pleural effusion/ascites as unique localization of disease.

- Patients with dyspnea due to presence of disease (lymphangitis) or requiring oxygen therapy.

- Patients with clinically evident hearth disease and/or active infectious diseases.

- Patients with not resected or not irradiated brain and/or leptomeningeal metastases.

- Prior or actual concurrent neoplasms, with the exception of adequately treated carcinoma della cervice uterina and basal cell or squamocellular carcinoma of the skin.

- Patients with uncontrolled serious illnesses that may compromise the compliance of the patient to the treatment.

- Previous allergic reactions towards any excipient in the composition of Trastuzumab or Lapatinib.

- Use of any experimental drug within 4 weeks prior initiation of study treatment.

- Women with childbearing potential who refuse to use adequate contraceptive measures.

- Patients unable to give written informed consent or are not compliant with treatment.

- Patients with great tumor involvement (> 30% dof hepatic volume, etc).
Locations
U.O. Oncologia Medica - Ospedale San Luigi
Orbassano, Torino, Italy
Status: Active, not recruiting
Institute for Cancer Research and Treatment (I.R.C.C.)
Candiolo , Torino, Italy
Status: Recruiting
U.O. Oncologia Medica
Cuneo, Italy
Status: Active, not recruiting
U.O. Oncologia Medica - COES Molinette
Torino, Italy
Status: Active, not recruiting
Start Date
February 2009
Completion Date
December 2011
Sponsors
Azienda Ospedaliera Ordine Mauriziano di Torino
Source
Azienda Ospedaliera Ordine Mauriziano di Torino
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page